Description
Retatrutide is an investigational “triple G” agonist (GLP-1, GIP, and glucagon receptor) being developed by Eli Lilly for obesity and Type 2 diabetes. Currently in Phase 3 trials and not yet FDA-approved, it has demonstrated significant, high-potency weight loss of up to 24-29% in studies. Side effects are generally gastrointestinal, and it is administered weekly.
The drug is currently in clinical trials. Any “retatrutide peptide” sold online outside of these trials is unregulated, not FDA-approved, and carries risks of contamination or incorrect dosage.
Reviews
There are no reviews yet.